SLEB1
MCID: SYS043
MIFTS: 39

Systemic Lupus Erythematosus 1 (SLEB1)

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Nephrological diseases, Rare diseases, Skin diseases

Aliases & Classifications for Systemic Lupus Erythematosus 1

MalaCards integrated aliases for Systemic Lupus Erythematosus 1:

Name: Systemic Lupus Erythematosus 1 57 74 29
Systemic Lupus Erythematosus, Resistance to 57 13
Sleb1 57 74
Systemic Lupus Erythematosus, Susceptibility to, 1 57
Lupus Erythematosus, Systemic, Type 1 40
Lupus Erythematosus, Systemic 72
Systemic Lupus Erythematosus 57

Classifications:



External Ids:

OMIM 57 601744
MeSH 44 D008180
UMLS 72 C0024141

Summaries for Systemic Lupus Erythematosus 1

UniProtKB/Swiss-Prot : 74 Systemic lupus erythematosus 1: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

MalaCards based summary : Systemic Lupus Erythematosus 1, also known as systemic lupus erythematosus, resistance to, is related to systemic lupus erythematosus 16 and systemic lupus erythematosus 2, and has symptoms including seizures and pruritus. An important gene associated with Systemic Lupus Erythematosus 1 is TLR5 (Toll Like Receptor 5). The drugs tannic acid and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include bone, skin and endothelial.

More information from OMIM: 601744

Related Diseases for Systemic Lupus Erythematosus 1

Diseases in the Lupus Erythematosus family:

Systemic Lupus Erythematosus Systemic Lupus Erythematosus 15
Systemic Lupus Erythematosus 1 Systemic Lupus Erythematosus 2
Systemic Lupus Erythematosus 3 Systemic Lupus Erythematosus 4
Systemic Lupus Erythematosus 5 Systemic Lupus Erythematosus 6
Systemic Lupus Erythematosus 7 Systemic Lupus Erythematosus 8
Systemic Lupus Erythematosus 9 Systemic Lupus Erythematosus 10
Systemic Lupus Erythematosus 11 Systemic Lupus Erythematosus 12
Systemic Lupus Erythematosus 13 Systemic Lupus Erythematosus 14
Systemic Lupus Erythematosus 16

Diseases related to Systemic Lupus Erythematosus 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1919)
# Related Disease Score Top Affiliating Genes
1 systemic lupus erythematosus 16 13.1
2 systemic lupus erythematosus 2 12.9
3 systemic lupus erythematosus 10 12.9
4 systemic lupus erythematosus 9 12.9
5 systemic lupus erythematosus 6 12.9
6 systemic lupus erythematosus 11 12.9
7 pediatric systemic lupus erythematosus 12.7
8 systemic lupus erythematosus with hemolytic anemia 1 12.7
9 systemic lupus erythematosus 3 12.7
10 systemic lupus erythematosus 4 12.7
11 systemic lupus erythematosus 7 12.7
12 systemic lupus erythematosus 15 12.7
13 systemic lupus erythematosus 8 12.7
14 systemic lupus erythematosus 13 12.7
15 systemic lupus erythematosus 5 12.7
16 systemic lupus erythematosus 12 12.7
17 systemic lupus erythematosus 14 12.7
18 systemic lupus erythematosus with nephritis 1 12.7
19 systemic lupus erythematosus with nephritis 2 12.7
20 systemic lupus erythematosus with nephritis 3 12.7
21 neonatal systemic lupus erythematosus 12.6
22 obsolete: bullous systemic lupus erythematosus 12.6
23 vitiligo-associated multiple autoimmune disease susceptibility 1 12.4
24 neonatal lupus erythematosus 12.4
25 mixed connective tissue disease 12.0
26 antiphospholipid syndrome 12.0
27 c1q deficiency 12.0
28 drug-induced lupus erythematosus 12.0
29 sjogren syndrome 12.0
30 cutaneous lupus erythematosus 11.9
31 hypogonadotropic hypogonadism 11.9
32 complement component 2 deficiency 11.9
33 raynaud phenomenon 11.8
34 aicardi-goutieres syndrome 11.8
35 spondyloenchondrodysplasia with immune dysregulation 11.8
36 systemic scleroderma 11.8
37 anemia, autoimmune hemolytic 11.8
38 fibromyalgia 11.8
39 macrophage activation syndrome 11.7
40 pure red-cell aplasia 11.7
41 progressive multifocal leukoencephalopathy 11.7
42 neuromyelitis optica 11.7
43 epidermolysis bullosa acquisita 11.7
44 rapidly progressive glomerulonephritis 11.7
45 distal renal tubular acidosis 11.7
46 chilblain lupus 1 11.7
47 jaccoud's syndrome 11.7
48 raynaud disease 11.7
49 complement component 3 deficiency, autosomal recessive 11.7
50 spondyloenchondrodysplasia 11.7

Graphical network of the top 20 diseases related to Systemic Lupus Erythematosus 1:



Diseases related to Systemic Lupus Erythematosus 1

Symptoms & Phenotypes for Systemic Lupus Erythematosus 1

Clinical features from OMIM:

601744

UMLS symptoms related to Systemic Lupus Erythematosus 1:


seizures, pruritus

Drugs & Therapeutics for Systemic Lupus Erythematosus 1

Drugs for Systemic Lupus Erythematosus 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 395)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
tannic acid Approved Phase 4 1401-55-4
2
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
3
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
4
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
5
Azathioprine Approved Phase 4 446-86-6 2265
6
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
7
Atorvastatin Approved Phase 4 134523-00-5 60823
8
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
9
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
10
Sulfamethoxazole Approved Phase 4 723-46-6 5329
11
Lifitegrast Approved Phase 4 1025967-78-5
12
Metformin Approved Phase 4 657-24-9 4091 14219
13
Simvastatin Approved Phase 4 79902-63-9 54454
14
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
15 Immunosuppressive Agents Phase 4
16 glucocorticoids Phase 4
17 Antineoplastic Agents, Hormonal Phase 4
18 Immunologic Factors Phase 4
19 Anti-Infective Agents Phase 4
20 Antimetabolites, Antineoplastic Phase 4
21 Alkylating Agents Phase 4
22 Antineoplastic Agents, Alkylating Phase 4
23 Antimalarials Phase 4
24 Antiparasitic Agents Phase 4
25 Antiprotozoal Agents Phase 4
26 Rosuvastatin Calcium Phase 4 147098-20-2
27 Chloroquine diphosphate Phase 4 50-63-5
28 Anthelmintics Phase 4
29 Hydroxycholecalciferols Phase 4
30 Ibandronic Acid Phase 4
31 Cytochrome P-450 Enzyme Inducers Phase 4
32 Immunoglobulin A Phase 4
33 Sodium Channel Blockers Phase 4
34 Diuretics, Potassium Sparing Phase 4
35 Anticonvulsants Phase 4
36 Cytochrome P-450 Enzyme Inhibitors Phase 4
37 Renal Agents Phase 4
38 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
39 Anti-Infective Agents, Urinary Phase 4
40 Angiogenesis Inhibitors Phase 4
41 Angiogenesis Modulating Agents Phase 4
42 Cyclosporins Phase 4
43 Lubricant Eye Drops Phase 4
44 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
45 Vaccines Phase 4
46 Hypoglycemic Agents Phase 4
47 Lipid Regulating Agents Phase 4
48 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
49 Hypolipidemic Agents Phase 4
50 Anticholesteremic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 737)
# Name Status NCT ID Phase Drugs
1 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in SLE Patients With Corticosteroid Therapy and High LDL Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
2 Endothelial Dysfunction in Systemic Lupus Erythematosus: Its Contribution to Abnormalities in Coronary Perfusion. Unknown status NCT00188188 Phase 4 quinipril
3 A Two-part Study Exploring the Efficacy, Safety, and Pharmacodynamics of Acthar in Systemic Lupus Erythematosus Patients With a History of Persistently Active Disease Unknown status NCT01753401 Phase 4 Acthar;Placebo for Acthar
4 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
5 Low Dose Aspirin and Statins for Primary Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus: A Randomized Double-blind Placebo-controlled Trial Completed NCT00371501 Phase 4 Rosuvastatin;placebo;aspirin;placebo
6 A Prospective, Randomised, Double-blind, Placebo-controlled Trial Evaluating the Effects of Mycophenolate Mofetil on 'Surrogate Markers' for Atherosclerosis in Female Patients With SLE. Completed NCT01101802 Phase 4 Mycophenolate mofetil;sugar pill
7 A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus Erythematosus (SLE) Completed NCT01632241 Phase 4 Standard therapy
8 Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis Completed NCT00125307 Phase 4 tacrolimus
9 A Phase 4, Multi-Center, Randomized, Open-Label Study to Evaluate the Effect of BENLYSTA™ (Belimumab; HGS1006) on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01597492 Phase 4
10 Study of the Reduction of Systemic Lupus Erythematosus Flares Through Adaptation of the Dosage of Hydroxychloroquine to Its Whole-blood Concentration. National Multicenter Randomized Prospective Study Completed NCT00413361 Phase 4 versus hydroxychloroquine
11 Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus, a Randomized, Double-blind, Placebo-controlled Clinical Trial Completed NCT01322308 Phase 4 pioglitazone;placebo
12 A Single-site, Investigator Initiated Open-Label Trial of H.P. Acthar Gel (Repository Corticotropin Injection)an Adrenocorticotropic Hormone (ACTH) Analogue in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) Completed NCT01769937 Phase 4 H.P. Acthar Gel
13 A Randomized, Double-blind, Placebo-controlled, Clinical Trial of Omega-3-polyunsaturated Fatty Acids in Subjects With SLE. Completed NCT00828178 Phase 4 Omega-3
14 Lupus Atherosclerosis Prevention Study Completed NCT00120887 Phase 4 Atorvastatin
15 Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With Systemic Lupus Erythematosus (SLE): a Controlled Study Completed NCT00911521 Phase 4 human papillomavirus vaccination (Gardasil)
16 Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus-Prevalence,Risk Factors and Treatment Completed NCT00668330 Phase 4 Ibandronate+alfacalcidol+calcium;placebo ibandronate+alfacalcidol+calcium
17 Randomized Controlled Trial to Evaluate the Efficacy of Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Induction and Maintenance of Remission of the Extra-renal Lupus Manifestations Completed NCT01112215 Phase 4 Azathioprine;Enteric-Coated Mycophenolate Sodium
18 Effect Of Hormone Replacement Therapy On Disease Activity, Menopausal Symptoms And Bone Mineral Density In Peri/Postmenopausal Women With Systemic Lupus Erythematosus.Randomized Clinical Trial Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
19 Immunogenicity and Safety of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases Completed NCT03540823 Phase 4
20 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
21 Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis Completed NCT01206569 Phase 4 Long-acting tacrolimus (Advagraf, Astellas Pharma)
22 Evaluation of Vaccination Against Influenza (Seasonal and H1N1) in Patients Presenting Systemic or Autoimmune Diseases Treated or Not With Steroids, and/or Immunosuppressant, and/or Biotherapy: an Open, Prospective Trial (MAIVAX) Completed NCT01065285 Phase 4
23 Comparison of Intravenous Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Proliferative Lupus Nephritis Completed NCT02645565 Phase 4 Cyclophosphamide;Azathioprine;Methylprednisolone
24 Renal Division, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease Completed NCT02351752 Phase 4 Hydroxychloroquine Sulfate
25 Possible Role of Chloroquine in Conjunction to Prednisone to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial Completed NCT02463331 Phase 4 Chloroquine diphosphate;prednisone;azathioprine
26 DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL WITH CHLOROQUINE VERSUS PLACEBO FOR MAINTENANCE OF REMISSION OF AUTOIMMUNE HEPATITIS Completed NCT01980745 Phase 4 Chloroquine diphosphate 250mg;Placebo
27 Estimation of Interleukin-21 Levels in Gingival Crevicular Fluid in Patients With Periodontal Health and Disease Following Non-surgical Periodontal Therapy: A Clinico-biochemical Study Completed NCT02861937 Phase 4
28 Phenytoin as an Augmentation for SSRI Failures: A Controlled Study Completed NCT00146237 Phase 4 phenytoin
29 A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Persistently Active Systemic Lupus Erythematosus Despite Moderate Dose Corticosteroids Recruiting NCT02953821 Phase 4 Repository corticotropin injection;Placebo gel
30 Prophylactic Trimethoprim-Sulfamethoxazole for the Prevention of Serious Infections in Patients With Systemic Lupus Erythematosus: a Randomized Placebo Controlled Trial Recruiting NCT03042260 Phase 4 Trimethoprim-Sulfamethoxazole;Placebo Oral Tablet
31 Efficacy, Safety, and Steroid Sparing Effect of Acthar in Patients With Hematologic Manifestations of Systemic Lupus Erythematosus Recruiting NCT02779153 Phase 4 Acthar low dose (40 U);Acthar high dose (80 U)
32 Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects Recruiting NCT03122431 Phase 4 Thalidomide;Hydroxychloroquine reduced;Hydroxychloroquine high
33 Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy Recruiting NCT02270970 Phase 4
34 Open-label Prospective Randomized Study to Determine the Efficacy and Safety of Two Dosing Regimens of ACTHar in the Treatment of Proliferative Lupus Nephritis. Recruiting NCT02226341 Phase 4 CellCept;ACTHar gel;ACTHar gel
35 Efficacy and Infectious Complications of Induction Therapy With Low-dose Versus High-dose Intravenous Cyclophosphamide for Proliferative Lupus Nephritis in Children Recruiting NCT01861561 Phase 4 Low-dose intravenous cyclophosphamide;High-dose intravenous cyclophosphamide
36 Effect of Hydroxychloroquine on Atrial Fibrillation Recurrence After Radiofrequency Catheter Ablation in Patients With Atrial Fibrillation Recruiting NCT03592823 Phase 4 Hydroxychloroquine Sulfate 200 Mg Tablet
37 Study Title: A Phase 4 Study to Assess the Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease Recruiting NCT03287635 Phase 4 Corticotropin 80Unit/Ml Repository Injection
38 A Multicenter, Randomised, Double-blind Placebo Controlled Trial on the Efficacy and Safety of add-on Metformin to Conventional Immunosuppressants in Systemic Lupus Erythematosus Active, not recruiting NCT02741960 Phase 4 metformin;placebo
39 A Randomized, Double-Blind, Active Comparator-Controlled, Crossover Study to Assess the Capacity of RAYOS® Compared to Immediate-Release Prednisone to Improve Fatigue and Control Morning Symptoms in Subjects With Systemic Lupus Erythematosus Active, not recruiting NCT03098823 Phase 4 RAYOS;Prednisone
40 A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab Active, not recruiting NCT01705977 Phase 4
41 Immunogenicity and Safety of a Herpes Zoster Vaccine (Zostavax) in Patients With Systemic Lupus Erythematosus: a Randomized Controlled Trial Active, not recruiting NCT02477150 Phase 4
42 Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease. Impact of Antirheumatic Treatment on Antibody Response. Active, not recruiting NCT03762824 Phase 4
43 Pilot Trial of Belimumab in Early Lupus Not yet recruiting NCT03543839 Phase 4
44 Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus Terminated NCT00739050 Phase 4 simvastatin;Comparator: Placebo
45 Protocol for a Randomized, Placebo-Controlled, Double-Blinded Trial to Study the Effects of Supplementary Omega-3 Fatty Acids on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
46 The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria Withdrawn NCT00508898 Phase 4 Calcitriol;Multivitamin
47 The Effect of Milnacipran on Fatigue and Quality of Life in a Lupus Cohort Withdrawn NCT01359826 Phase 4 Milnacipran
48 Pilot Double-Blind Placebo Controlled Trial of Levothyroxine in Pregnant Systemic Lupus Erythematosus (SLE) Patients With Autoimmune Thyroid Disease Withdrawn NCT01276782 Phase 4 Levothyroxine
49 An Open Label Randomized Phase IV Study of the Safety and Efficacy of ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis Withdrawn NCT01926054 Phase 4 Acthar gel
50 Use of the GnRH Agonist Leuprolide Acetate (Lupron(Registered Trademark)) to Preserve Ovarian Function in Women Undergoing Chemotherapy Withdrawn NCT00507780 Phase 4 GnRH antagonist

Search NIH Clinical Center for Systemic Lupus Erythematosus 1

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Azathioprine
Cyclosporine
Hydroxychloroquine
Hydroxychloroquine Sulfate
Triamcinolone
Triamcinolone Acetonide
TRIAMCINOLONE ACETONIDE PWDR
triamcinolone diacetate
triamcinolone hexacetonide

Genetic Tests for Systemic Lupus Erythematosus 1

Genetic tests related to Systemic Lupus Erythematosus 1:

# Genetic test Affiliating Genes
1 Systemic Lupus Erythematosus 1 29 TLR5

Anatomical Context for Systemic Lupus Erythematosus 1

MalaCards organs/tissues related to Systemic Lupus Erythematosus 1:

41
Bone, Skin, Endothelial, Heart, B Cells, T Cells, Kidney

Publications for Systemic Lupus Erythematosus 1

Articles related to Systemic Lupus Erythematosus 1:

(show top 50) (show all 62)
# Title Authors PMID Year
1
A stop codon polymorphism of Toll-like receptor 5 is associated with resistance to systemic lupus erythematosus. 8 71
16027372 2005
2
Impaired TLR5 functionality is associated with survival in melioidosis. 71
23447684 2013
3
Regulation of B cell tolerance by the lupus susceptibility gene Ly108. 8
16778059 2006
4
A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires' disease. 71
14623910 2003
5
The major murine systemic lupus erythematosus susceptibility locus, Sle1, is a cluster of functionally related genes. 8
11172029 2001
6
Genome scan of human systemic lupus erythematosus: evidence for linkage on chromosome 1q in African-American pedigrees. 8
9843982 1998
7
Genetic dissection of SLE pathogenesis. Sle1 on murine chromosome 1 leads to a selective loss of tolerance to H2A/H2B/DNA subnucleosomes. 8
9502778 1998
8
Susceptibility loci for lupus: a guiding light from murine models? 8
9045853 1997
9
Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. 8
9045876 1997
10
[Etiologies and risk factors for young people with intracerebral hemorrhage]. 38
30643071 2018
11
Gastrointestinal Tract Vasculopathy: Clinicopathology and Description of a Possible "New Entity" With Protean Features. 38
29624512 2018
12
Intramuscular Steroids in the Treatment of Dermatologic Disease: A Systematic Review. 38
29537450 2018
13
Yield of Screening Tests for Systemic Vasculitis in Young Adults with Ischemic Stroke. 38
30716738 2018
14
Etiological profile of noncompressive myelopathies in a tertiary care hospital of Northeast India. 38
28298841 2017
15
[Risk factors for long-term result of endovascular treatment for auto-immune disease related abdominal aorta pseudo-aneurysm]. 38
27978898 2016
16
Epidemiology of rheumatic diseases in Mixtec and Chontal indigenous communities in Mexico: a cross-sectional community-based study. 38
26689797 2016
17
Clinical features and outcome of acute exacerbation of interstitial pneumonia associated with connective tissue disease. 38
27644575 2016
18
Association of Extrahepatic Manifestations with Autoimmune Hepatitis. 38
26641498 2015
19
Autoantibodies against CD74 in spondyloarthritis. 38
23687263 2014
20
Corticoid-associated complications in elderly. 38
23197053 2012
21
Association of ferritin autoantibodies with giant cell arteritis/polymyalgia rheumatica. 38
22228484 2012
22
Sternal insufficiency fractures of post-menopausal women: retrospective analysis of 17 cases. 38
22770409 2012
23
[Retrospective evaluation of the ten-year experience of a single coeliac centre]. 38
22580504 2012
24
Evaluation of pulse wave velocity in systemic lupus erythematosus, rheumatoid arthritis and Behçet's disease. 38
22079854 2012
25
[Role of plasmapheresis in immunological kidney diseases. Experience from 1050 completed plasmapheresis treatment sessions]. 38
21712172 2011
26
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. 38
19264918 2009
27
Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. 38
17376507 2007
28
Subcellular localization of a germiantion-specific cortex-lytic enzyme, SleB, of Bacilli during sporulation. 38
16905870 2006
29
[Systemic lupus erythematosus presenting with a choreo-athetosic syndrome associated with antiphospholipid antibodies]. 38
16365627 2005
30
Several genes contribute to the production of autoreactive B and T cells in the murine lupus susceptibility locus Sle1c. 38
16002709 2005
31
Inflammatory aortic aneurysm is associated with increased incidence of autoimmune disease. 38
12947264 2003
32
Kikuchi's disease: a review and analysis of 61 cases. 38
12748557 2003
33
Malignant lymphoma-associated autoimmune diseases--a descriptive epidemiological study. 38
12426661 2002
34
[Role of anti-prothrombin in antiphospholipid syndrome]. 38
12404033 2002
35
[Prevalence and clinical features of fibromyalgia in systemic lupus erythematosus, systemic sclerosis and Sjögren's syndrome]. 38
12094151 2002
36
Exposure to solvents in female patients with scleroderma. 38
12086160 2002
37
Determination of autoantibodies to annexin XI in systemic autoimmune diseases. 38
11035417 2000
38
Increased in vitro production of interleukin 6 in response to trimethoprim among persons with trimethoprim induced systemic adverse reactions. 38
10606366 1999
39
Methotrexate-induced papular eruption in patients with rheumatic diseases: a distinctive adverse cutaneous reaction produced by methotrexate in patients with collagen vascular diseases. 38
10321597 1999
40
Lymphoscintigraphy in chyluria, chyloperitoneum and chylothorax. 38
9669413 1998
41
Myelodysplastic syndromes and acute myeloid leukemia in connective tissue disease after single-agent chemotherapy. 38
8929481 1996
42
Lymphocytes, cytokines, inflammation, and immune trafficking. 38
8941441 1996
43
[Clinical study on Fournier's gangrene--value of "through and through drainage"]. 38
7609356 1995
44
Clinical, serological and immunogenetic features of Japanese anti-Ro/SS-A-positive patients with annular erythema. 38
8049546 1994
45
[Association of autoimmune disease in primary biliary cirrhosis]. 38
8114302 1994
46
[A high-resolution computed tomographic study of the pulmonary interstitium in systemic autoimmune diseases]. 38
8128031 1994
47
[Detection of circulating antibodies in the blood and immune complex precipitates of patients with autoimmune diseases (preliminary report)]. 38
1579350 1992
48
[Systemic lupus erythematosus. 1. Disease manifestations, infections, thrombotic episodes, causes of death and survival in a case load of 173 patients followed for 13.9 years]. 38
2058038 1991
49
Retrovirus-like particles in human thymomas. 38
2130528 1990
50
Magnetic resonance imaging of the fetus: initial experience. 38
2361632 1990

Variations for Systemic Lupus Erythematosus 1

Expression for Systemic Lupus Erythematosus 1

Search GEO for disease gene expression data for Systemic Lupus Erythematosus 1.

Pathways for Systemic Lupus Erythematosus 1

GO Terms for Systemic Lupus Erythematosus 1

Sources for Systemic Lupus Erythematosus 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....